Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01199198 · ClinicalTrials.gov registry record · Phase 4
Tolvaptan in Hyponatremic Cancer Patients
A Phase 4 study of Advanced Cancers, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 52
- Enrollment target
- 1
- Study location
NCT01199198 is a Phase 4 study of Advanced Cancers that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 52 participants, below the 65-participant average among 10 other Advanced Cancers trials with a reported enrollment target (20% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01199198, a Phase 4 study of Advanced Cancers, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 52 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical research study is to learn if tolvaptan can help raise salt (sodium) levels in the cancer patients' blood by removing extra body water as urine.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Tolvaptan
Study Locations (1)
Texas
- UT MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2011-05 |
| Est. Completion | 2013-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01199198
The ClinicalTrials.gov registry entry for NCT01199198 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 65-participant average among 10 other Advanced Cancers trials with a reported enrollment target (20% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Cancers appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01199198 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT01199198 about?
NCT01199198 is a clinical study titled "Tolvaptan in Hyponatremic Cancer Patients". The goal of this clinical research study is to learn if tolvaptan can help raise salt (sodium) levels in the cancer patients' blood by removing extra body water as urine.
What is the current status of trial NCT01199198?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 52 participants. The study started on 2011-05. Estimated completion is 2013-09.
What conditions does trial NCT01199198 study?
This clinical trial studies the following conditions: Advanced Cancers.
What interventions are being tested in trial NCT01199198?
The interventions under investigation include: Placebo (DRUG), Tolvaptan (DRUG).
Who is sponsoring clinical trial NCT01199198?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01199198 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Cancers
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Psilocybin in Cancer Pain Study
RECRUITING · Phase 2
-
Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies
ACTIVE NOT RECRUITING · Phase 1
-
The Effects of Ginseng on Cancer-Related Fatigue
ACTIVE NOT RECRUITING · Phase 1
-
Study of Vemurafenib, Carboplatin, and Paclitaxel
COMPLETED · Phase 1
-
Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.